Home / AZD-3759 CAS 1626387-80-1

AZD-3759 CAS 1626387-80-1

  • Name: AZD-3759
  • Synonyms: (2R)-2,4-Dimethyl-1-piperazinecarboxylic acid 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl est
  • Molecular Formula: C22H23ClFN5O3
  • CAS No.: 1626387-80-1
  • EC No.:
  • Molecular Weight: 459.901

【Product name】: AZD-3759

【CAS No.】: 1626387-80-1

【Appearance】: White to off-white crystalline powder

【Purity】; ≥99%， HPLC available

【Storage】：Store at room temperature, sealed and protected from light

【Description】: AZD3759 is a new drug developed by AstraZeneca and is not yet on the market. Although this drug also targets EGFR in lung cancer, AZD3759 is mainly designed to effectively cross the blood-brain barrier to resolve central nervous system metastases, such as brain metastases and meningeal metastases, in patients with non-small cell lung cancer with EGFR-sensitive mutations. AZD3759 is currently undergoing Phase I/II research and development. Judging from the current clinical trials, AZD3759 first has the basic efficacy of EGFR target drugs such as Iressa and Tarceva, and focuses on patients with brain metastases. The dose of AZD3759 should be at least 50mg-100mg twice daily. The most common side effects of AZD3759 were similar to those of Iressa, including rash (45% overall) and diarrhea (59% overall).